Background: Intensive insulin treatment is bothersome in obese patients with type 2 diabetes mellitus. High insulin dosages further increase weight gain and the risk of hypoglycemia. Glucagon like peptide-1 receptor agonists decrease the insulin need, cause weight loss and reduce the risk of hypoglycemia. There is limited data about the effect of exenatide on obese diabetics under intensive insulin regimens.
Methods: This retrospective case series report the clinical outcomes of 23 obese (13 morbidly obese) patients with uncontrolled type 2 diabetes mellitus (Age=59±10.44 years, body mass index 41.1±6.8 kg/m2, HbA1c 9.9±1.5%), under high dose (94.1±39.6 unit) intensive insulin. Exenatide twice daily was added for a mean follow-up period of 11.22±7.01 (3–30) months. Intensive insulin regimens were continued in 7 patients while the others were switched to basal insulin during the follow-up.
Results: During the follow-up, mean HbA1c levels of the patients significantly improved (p=0.019), along with the significant decrease in body mass index and the total insulin need (p<0.001 for both). Baseline insulin dosages were significantly higher in the intensive regimen group (p=0.013) while other demographical and clinical characteristics were similar. No significant difference was present between the groups regarding the alterations of HbA1c, body mass index and the reduction in total insulin dosages.
Conclusion: Add on exenatide appears to be a rational treatment modality in uncontrolled obese patients with type 2 diabetes mellitus despite intensive insulin regimens. Further prospective randomized studies with longer follow-up periods are recommended.
References
1 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 2012; 35: 1364-1379
3 Kjems LL, Holst JJ, Volund A et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380-386
5 Rizzo M, Abate N, Chandalia M et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. The Journal of clinical endocrinology and metabolism 2015; 100: 603-606
6 Rizvi AA, Patti AM, Giglio RV et al. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert opinion on biological therapy 2015; 15: 1391-1397
7 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 2015; 38: 140-149
8 Nauck M, Rizzo M, Johnson A et al. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes care 2016; 39: 1501-1509
9 Eng C, Kramer CK, Zinman B et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet (London, England) 2014; 384: 2228-2234
10 Lane W, Weinrib S, Rappaport J et al. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes, obesity & metabolism 2014; 16: 827-832
11 Lind M, Hirsch IB, Tuomilehto J et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ (Clinical research ed) 2015; 351: h5364
12 Viswanathan P, Chaudhuri A, Bhatia R et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2007; 13: 444-450
13 Yoon NM, Cavaghan MK, Brunelle RL et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clinical therapeutics 2009; 31: 1511-1523
14 Lind M, Jendle J, Torffvit O et al. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Primary care diabetes 2012; 6: 41-46
15 Arakaki RF, Blevins TC, Wise JK et al. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial. Diabetes, obesity & metabolism 2014; 16: 510-518
16 Vilsboll T, Christensen M, Junker AE et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed) 2012; 344: d7771
17 Gan Y, Dang N, Qu Z et al. GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 2015; 123: 371-375
18 Hurt RT, Kulisek C, Buchanan LA et al. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterology & hepatology 2010; 6: 780-792
19 Gustafson B, Smith U. Regulation of white adipogenesis and its relation to ectopic fat accumulation and cardiovascular risk. Atherosclerosis 2015; 241: 27-35
21 Sjostrom L, Peltonen M, Jacobson P et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. Jama 2014; 311: 2297-304
22 Pi-Sunyer X, Astrup A, Fujioka K et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015; 373: 11-22
